The U.S. AI-Driven Retinal Screening Device Market was valued at USD 851.4 million in 2024 and is estimated to grow at a CAGR of 11.7% to reach USD 2.6 billion by 2034.
The market is fueled by the rising prevalence of diabetic retinopathy and age-related eye conditions, advancements in deep learning and image recognition, and growing awareness around early eye disease detection. The expanding geriatric population and increasing emphasis on preventive eye care are further accelerating adoption. AI-enabled retinal screening systems deliver rapid, reliable evaluations of retinal abnormalities, and their integration into ophthalmology clinics, primary care centers, pharmacies, and mobile units is improving access to advanced eye diagnostics. As healthcare shifts toward proactive, technology-driven eye care, AI-based screening tools are increasingly essential for detecting retinal conditions early and enhancing patient outcomes across diverse care settings. Recent innovations in deep learning have significantly enhanced the precision and efficiency of image-based diagnostics. AI algorithms can identify subtle retinal changes often missed by human observation, enabling earlier, more accurate diagnoses. These systems continuously improve through learning algorithms, increasing their effectiveness over time.
The diabetic retinopathy segment generated USD 461.7 million in 2024. AI-driven screening is transforming diabetic retinopathy diagnosis by enabling early, autonomous assessments in primary care environments. These systems analyze retinal images for microaneurysms, hemorrhages, and other disease indicators, often reducing the need for specialist reviews and accelerating treatment initiation.
The hospitals segment held 50.6% share in 2024, benefiting from high patient volumes and the capacity to invest in advanced technology. Hospitals are deploying AI retinal screening devices to streamline diagnostics, enhance efficiency, and reduce specialist workloads, particularly during routine examinations and chronic disease management programs.
South Atlantic AI-Driven Retinal Screening Device Market held a 19.6% share in 2024. States in this zone are witnessing strong uptake due to a sizable elderly population and high diabetes prevalence. Healthcare providers are integrating AI retinal screening into primary care and community clinics to support early detection and alleviate pressure on specialists. Telehealth adoption and mobile screening units are also expanding, making AI solutions critical for preventive eye care, especially in underserved areas.
Key players in the U.S. AI-Driven Retinal Screening Device Market include Topcon Healthcare, Visionix, EYENUK, DIGITAL DIAGNOSTICS, AEYE Health, Notal Vision, iCare, Remidio, Evolucare, Optomed, and Forus Health. Companies in the U.S. AI-Driven Retinal Screening Device Market are adopting several strategies to strengthen their foothold. They are investing in research and development to enhance AI algorithms for improved diagnostic accuracy and broader disease detection. Strategic partnerships with healthcare providers, telemedicine platforms, and technology firms expand market reach and integration. Firms are also focusing on training programs for clinicians and technicians to ensure seamless adoption. Product diversification, mobile and cloud-based solutions, and targeted marketing campaigns help increase accessibility and awareness.
This product will be delivered within 2-4 business days.
The market is fueled by the rising prevalence of diabetic retinopathy and age-related eye conditions, advancements in deep learning and image recognition, and growing awareness around early eye disease detection. The expanding geriatric population and increasing emphasis on preventive eye care are further accelerating adoption. AI-enabled retinal screening systems deliver rapid, reliable evaluations of retinal abnormalities, and their integration into ophthalmology clinics, primary care centers, pharmacies, and mobile units is improving access to advanced eye diagnostics. As healthcare shifts toward proactive, technology-driven eye care, AI-based screening tools are increasingly essential for detecting retinal conditions early and enhancing patient outcomes across diverse care settings. Recent innovations in deep learning have significantly enhanced the precision and efficiency of image-based diagnostics. AI algorithms can identify subtle retinal changes often missed by human observation, enabling earlier, more accurate diagnoses. These systems continuously improve through learning algorithms, increasing their effectiveness over time.
The diabetic retinopathy segment generated USD 461.7 million in 2024. AI-driven screening is transforming diabetic retinopathy diagnosis by enabling early, autonomous assessments in primary care environments. These systems analyze retinal images for microaneurysms, hemorrhages, and other disease indicators, often reducing the need for specialist reviews and accelerating treatment initiation.
The hospitals segment held 50.6% share in 2024, benefiting from high patient volumes and the capacity to invest in advanced technology. Hospitals are deploying AI retinal screening devices to streamline diagnostics, enhance efficiency, and reduce specialist workloads, particularly during routine examinations and chronic disease management programs.
South Atlantic AI-Driven Retinal Screening Device Market held a 19.6% share in 2024. States in this zone are witnessing strong uptake due to a sizable elderly population and high diabetes prevalence. Healthcare providers are integrating AI retinal screening into primary care and community clinics to support early detection and alleviate pressure on specialists. Telehealth adoption and mobile screening units are also expanding, making AI solutions critical for preventive eye care, especially in underserved areas.
Key players in the U.S. AI-Driven Retinal Screening Device Market include Topcon Healthcare, Visionix, EYENUK, DIGITAL DIAGNOSTICS, AEYE Health, Notal Vision, iCare, Remidio, Evolucare, Optomed, and Forus Health. Companies in the U.S. AI-Driven Retinal Screening Device Market are adopting several strategies to strengthen their foothold. They are investing in research and development to enhance AI algorithms for improved diagnostic accuracy and broader disease detection. Strategic partnerships with healthcare providers, telemedicine platforms, and technology firms expand market reach and integration. Firms are also focusing on training programs for clinicians and technicians to ensure seamless adoption. Product diversification, mobile and cloud-based solutions, and targeted marketing campaigns help increase accessibility and awareness.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Zone, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies featured in this U.S. AI-Driven Retinal Screening Device market report include:- AEYE Health
- DIGITAL DIAGNOSTICS
- evolucare
- EYENUK
- Forus Health
- iCare
- NOTAL VISION
- OPTOMED
- remidio
- Topcon Healthcare
- Visionix
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | November 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 851.4 Million |
| Forecasted Market Value ( USD | $ 2600 Million |
| Compound Annual Growth Rate | 11.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 12 |
